Evidence map›Paper›PMID 34555178›Full record

ArticleClinical pharmacology and therapeutics2021

Informing and Validating Translational Mechanism-Based Models for Antibiotics by Experimental and Computational Approaches.

Jürgen B Bulitta

Abstract readLetterComment
In one paragraph

Article in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Jürgen B BulittaDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.

Funding

Combating resistant superbugs by understanding the molecular determinants of target site penetration and bindingR01AI136803 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$5.7M
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative SuperbugsR01AI111990 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LI, JIAN, TSUJI, BRIAN · 2014 to 2018
$4.4M
Novel Strategies for Antibiotic Combinations to Combat Gram-negative SuperbugsR01AI148560 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BULITTA, JURGEN BERND, TSUJI, BRIAN · 2020 to 2024
$3.9M
Next-generation combination dosing strategies to combat resistant Acinetobacter baumanniiR01AI130185 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$3.4M
NIAID NIH HHS R01 AI111990NIAID NIH HHS R01 AI130185NIAID NIH HHS R01 AI136803NIAID NIH HHS R01 AI148560
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsComputational BiologyHumansProteomicsTranslational Research, BiomedicalAnti-Bacterial Agents

Identifiers

PMID34555178
PMCPMC10609266

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.